Reopening, Vaccine Distribution, & $1.9T Stimulus Hopes Turbo Charged The Markets This Week

It was certainly an amazing week in the markets as we rebounded strongly after last week’s selloff while seemingly being turbo charged with high octane fuel. In fact it was best weekly performance since November. The fuel came primarily in the form of a growing understanding that the economy is further opening/poised to gain momentum later in 2021, the distribution of the COVID-19 vaccination was finally being organized, & that the $1.9 trillion stimulus package would be all coming in to play in a town near you soon.

The indices reached records along the way and ended the week significantly higher. The S&P 500 closed at 3,886.83 (+4.6% wk/wk) (+3.5 YTD), the Dow ended at 31,148.24 (+3.9% wk/wk) (+1.8 YTD), & the Nasdaq Composite closed at 13,856.30 (+6% wk/wk ) (+7.5 YTD) while the Russell 2000 enjoying the best move of the week closing at 2,233.33 (+7.7%) (+13.5% wk/wk) (+5 YTD). All sectors ended in the green this week with the energy sector leading the the pack jumping 8.3% after falling 6.6% last week. Oil prices rose to $56.89/bbl, up over $4/bbl week over week. 

 JOE’s STIMULUS & VACCINATION DISTRIBUTION

President Joe Biden’s recently introduced $1.9T stimulus package got a significant boost this week as the House passed a budget resolution that enables a budget reconciliation process as it will now only require a simple majority to pass. Also, we now have the likes of CVS Health (CVS) & Walgreens (WBA) finally being weaved into the vaccination distribution fabric, not to mention, Disney (DIS) & NFL stadiums, we seem to finally be getting our collective heads around this serious endeavor. 

THE “MACRO”

The macroeconomic schedule also produced a number of reports as follows this week that showed improvement in many cases. On Monday, the ISM Manufacturing Index report for January showed a drop to 58.7%, but still well above the expansion level of 50. The Total construction spending report confirmed a rise by 1% month/month in December. The Total private construction spending report showed a rise by 1.2% month/month while total public construction spending rose by .5%. The January IHS Markit Manufacturing PMI moved up to 59.2. On Wednesday, we received the ISM Non-Manufacturing Index report which confirmed a move up to 58.7% in January. The ADP Employment Change report also estimated that 174k jobs were added to private-sector payrolls in January. The IHS Markit Services PMI for January got adjusted higher to 58.3 in the preliminary reading. On Thursday, the initial jobless claims report for the week ending January 30 which confirmed a drop by 33k to 779k while continuing claims for the week ending January 23 dropped by 193k to 4.592M. Productivity in Q4 was reported to have dropped quarter over quarter at an annual rate of 4.8% while Q3 productivity was revised upward to a 5.1% rise. The Unit labor costs report showed a rise to an annual rate of 6.8%. However, Factory orders for manufactured goods rose 1.1% month/month in December, confirming 8 consecutive monthly increases in factory orders. On Friday, the January nonfarm payrolls were confirmed to have risen by 49k while private sector payrolls rose by 6k. The January unemployment rate came in at 6.3% improving again from December. The December Trade Balance Report confirmed a further a narrowing in the trade deficit to -$66.6B. The Consumer credit confirmed a rise by $9.7B in December 

Next week, we will receive the small-business optimism report on Tuesday, the inflation report on Wednesday, & the consumer confidence report on Friday.

TECH HIGHLIGHTS

Shares of Microsoft (MSFT) closed at $242.20/share, +.08% Friday & up nicely from last Friday’s close of $231.96/share after reporting better than expected earnings recently. Intel (INTC) closed at $58.18, -1.04% Friday, moving up from last Friday’s $55.51/share. Bob Swan, Intel’s outgoing CEO, bought more than $1.5M of Intel’s stock after they reported on Jan. 22.

Salesforce (CRM) closed at $238.89, +.38% on Friday nicely from last Friday’s close of $225.56. As per reports, Salesforce Inc. (CRM) will launch Vaccine Cloud to assist healthcare providers and the government to globally record, manage, maintain records of COVID-19 vaccinations digitally. The vaccine Cloud will assist people to register and schedule for their vaccine shots, share their vaccination or health status updates helping bring back employees to offices.

“The biggest challenge the world faces right now is orchestrating the distribution of billions of vaccine doses. Technology can play a critical role,” stated Salesforce President and Chief Operating Officer Bret Taylor.

Peter Thiel co-founded software firm Palantir Technologies (PLTR) closed at $34.05/share, +6.24% Friday but down from the $35.18/share close last week. PLTR deepened their ties with BP this week with a new 5-year deal.

Leading EV car maker Tesla (TSLA) closed at $852.23, +.26% Friday up nicely from $793.53 last Friday. Chinese EV concern NIO Limited (NIO) closed at $56.67, -1.61% on Friday down from $57/share last Friday. 

The ever so popular FAANG’s ended lower Friday as follows: Apple (AAPL) shares closed at $136.76 up last Friday’s close of $131.96, Amazon (AMZN) closed at $3,352.15 up from last Friday’s close of $3,206.20 after reporting that Jeff Bezos is stepping down as CEO, Alphabet (GOOG) closed at $2,098 up strongly from last Friday’s close of $1,835.74, Facebook (FB) closed at $268.10 up from last Friday’s close of $258.33, & Netflix (NFLX) closed at $550.79 up from last Friday’s close of $532.39/share.

ACROSS THE DOW 30

Johnson & Johnson (JNJ) closed at $164.45/share, +1.52% Friday & up from last week’s close of $163.13 as they reported that they applied for Emergency use of it single-dose COVUD-19 vaccine candidate. Pharmaceutical giant Merck (MRK) closed at $75.80/share, -.30% Friday shaving of another ~2 points from last Friday’s close of $77.07/share. 

Shares of Coca-Cola (KO) closed at $49.65/share up from last Friday’s close of $48.15/share. Shares of Disney (DIS) closed at $181.16/share, +.52% on Friday & up sharply from last Friday’s at $168.17/share. Shares of Nike (NKE) closed at $145.11/share up from last Friday’s close at $133.59/share. Walmart (WMT) closed at $144.36/share up from last Friday’s close of $140.49/share. 

Shares of Deere (DE) closed at $309.24/share, -.01% Friday, but up again from last week’s Friday close of $288.80/share. John Deere recently added four companies to its 2021 Startup Collaborator program this week. These startups are Nori, NVision Ag, Scanit, and Teleo. The Startup Collaborator program helps John Deere deepen its interaction with startup companies whose technology could add value for John Deere customers in the future. Caterpillar (CAT) closed at $193/share, +.7% & up from last Friday’s close of $182.84/share. Caterpillar, Inc. (CAT) has completed the acquisition of the Oil & Gas Division, “Weir Oil & Gas” of the Weir Group PLC, a Scotland-based global engineering business. SPM Oil & Gas, Headquartered near Fort Worth, Texas will continue to produce flow iron, a full line of pumps, wellhead and pressure control products, and consumable parts offered via an extensive global network of service centers. The deal includes more than 40 global service centers and approximately 2,000 employees.

Boeing (BA) closed $207.93, -1.29% on Friday but up from last Friday’s close of $194.19/share. Morgan Stanley recently upgraded Boeing as a ‘COVID-19 recovery play.

The Home Depot, Inc. (HD) has opened a new 1.5 million-square-foot distribution center in Dallas to fulfill its online orders and store orders. The store is designed to meet customers’ delivery needs through various channels, including delivering items directly to customers’ homes or for pickup at local stores. The store also offers and manages customer delivery and installation of large electrical appliances such as dryers, washers, and refrigerators ordered in stores or online.

Reportedly, the board of 3M announced its common stock dividend of $1.48 per share for the first quarter of 2021, to be paid on March 12, 2021, to shareholders at the close of business on February 12, 2021. The dividend is an increase of 1 percent over the quarterly dividend paid in 2020 marking it the 63rd consecutive year the company has increased its dividend.

BIOTECH

iShares Nasdaq Biotechnology ETF (IBB) closed at $169.05 up 9 points from last week’s close of $160.64. The NYSE ARCA Biotech Index (^BTK) closed at 6,237.92 up from last week’s close of 5,984.62. 

On Wednesday GW Pharmaceuticals (Nasdaq: GWPH) ($211.37, +44.5%),  a firm focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas announced that it will be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) ($151.21, -3.9%) for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. Who will be next?

FINANCIALS

Around the sector, Goldman Sachs (GS) closed trading at $293.50/share, -.09% Friday but up from last Friday’s close of $271.17/share, American Express (AXP) closed at $126.28/share, +1.1% on Friday & up ~$10 from the $116.26/share close last Friday, Visa (V) closed trading at $208.77/share, -.231% Friday but up from the $193.25/share close last Friday & shares of Morgan Stanley (MS) closed at $83.22/share, +1.29% Friday & up from last Friday’s close of $67.05/share. JPMorgan Chase (JPM) closed at $137.98, -.2% Friday but up from the $128.67/share close last Friday & Citigroup (C) $62.58/share up from the close of $57.99/share last week. PayPal Holdings (PYPL) closed at $269.44/share up from last Friday’s close of $234.31/share after posting a high Q4 and Square (SQ) closed at $240.38 up from last week’s close of $215.96/share after it was reported that they were picking up Caash App users amid the “Robinhood drama”.

Thomas J. Baltimore, Jr., Chairman, Chief Executive Officer, and President of Park Hotels & Resorts Inc. has been elected to be a part of the American Express (AXP), Board of Directors effective January 27, 2021. Mr. Baltimore was elected Chairman of the Park Hotels & Resorts’ Board in 2017. He has been in service with Park Hotels & Resorts since 2016 shortly before its spin-off from Hilton Worldwide Inc.

JPMorgan Chase & Co (JPM) is set to launch a digital retail bank under its Chase brand with headquarters in Canary Wharf, London with a contact center in Edinburgh. The bank will provide products and features tailored to meet the needs of customers in the U.K.

GOLD & SILVER MARKETS

Gold prices closed at $1816 down again from the $1,849/oz. close last week. This Friday silver prices closed at $27.01/oz. slightly off from the $27.11/oz. close last Friday. Barrick Gold Corp. (GOLD) closed trading at $22.33 down slightly from last Friday’s close of $22.37/share. North American silver and gold producer Hecla Mining Company (HL) ended the week at $6.12/share slightly up from last Friday’s close of $5.69/share.  Phillips S. Baker, Jr., President, and CEO of Hecla Mining Company (NYSE: HL), discussed “The Silver Squeeze” while addressing questions from the Tribe Public were he offered valuable insights on silver prices throughout history and the recent volatility that helped move silver related stocks & silver prices. Please view the event video now. 

MONEY UPDATE

The U.S. Dollar Index strengthened to end the week at 90.99 marginally up from 90.55 last Friday.  The 2-yr Treasury yield closed lower at .09% compared to the prior week at .111%, the 10-yr yield closed up 8 basis points ending at 1.17% while the 30-yr yield ended at 1.97% ticking up from 1.833% last Friday.

TRADING NEXT WEEK 

A full week of trading is in line for us next week.

STOCKS IN VIEW NEXT WEEK

• Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed at $16.15 up from the $14.17 close last week. This week, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.

• • I hosted Chinook’s President & CEO Eric Dobmeier at our sister organization Tribe Public’s Presentation and Q&A event, Tuesday, Jan. 26th which you can watch now at Tribe Public YouTube Channel. Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

• • Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

• • Chinook has well-funded development programs with participation in a $115 million private placement financing concurrent with the close of a merger with Aduro Biotech in Q4 2020 from top-tier healthcare investors including, EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and others.

• Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $105.19/share up from $90.63 last Friday still shy of its recently achieved a new all-time high of $121.16.  Recently, FATE announced the pricing of an underwritten public offering of ~$432 million at $85.50. Jefferies, BofA Securities, SVB Leerink and Barclays acted as joint book-running managers for the offering.  We started with this one folks over 3 years ago when it was in the $3 range.

• • Fate is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.

• • Recently, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab. Our recent Phase 1 clinical data with FT516 in combination with rituximab, which demonstrate the potential of our novel hnCD16 Fc receptor to potentiate ADCC and drive complete responses, support our belief that the multi-antigen targeting functionality of FT596 may offer best-in-class potential for patients with B-cell malignancies.” 

• • We have made another investment in a private company called Cytovia Therapeutics that owns its own NK cell platform that some investors are calling “FATE 2.0”. They are seeking to go next year in Q2/Q3 as there is room in the markets for another NK cell company. Their website is www.cytoviatx.com.

• Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS) closed at $3.81/share up from $2.21/share last week after reaching an intraday and YTD high of $4.90 now with an average trading volume of 18.57M/day and a $278.42 M MKT Cap.  This move came after Atossa Therapeutics, Inc. (Nasdaq:ATOS) recently announced updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen. “To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator. “This patient, like many breast cancer patients, was reluctant to take tamoxifen because of the well-documented side effects associated with that drug and because she lacked the proper liver enzymes to properly metabolize tamoxifen. We are very encouraged by this patient’s experience with our Endoxifen over the past two years. Her experience serves as a model for ongoing development efforts,” commented Steve Quay, Ph.D., M.D., Atossa’s President and CEO.  Yesterday, I hosted  Tribe Public’s Webinar Presentation and Q&A Event with Steven Quay, MD, PhD, CEO & Founder & Kyle Guse CFO of Atossa Therapeutics (NASDAQ: ATOS) who delivered a presentation titled “The Important Role of COVID-19 Therapeutics In A Post-Vaccine World.” They also addressed Q&A session at the end of the presentation. Please view it here.

• • Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.

  • Atossa recently announced blinded preliminary results from its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was found to be safe and well tolerated in this study at two different dose levels in both single and multiple dose forms over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. Learn more now.

• • Atossa announced that it has received $21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021. Kyle Guse, CFO and General Counsel stated, “In the past 60 days, we have made great progress in adding substantial cash resources so that we can accelerate development of our COVID-19 and breast cancer therapies. We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants. We look forward to the speed at which we can now advance our programs in 2021.”

• • Atossa is seeking in the near term to get an FDA nod to move into a Phase 2 trial with its nasal spray COVID-19 therapy.

• Shares of INVO Bioscience (NASDAQ: INVO) closed at $3.32/share up from $2.96 close last Friday. INVO has closed soundly above its 50-day moving average of $3.10. There appears to be a significant gap up to its $5.14 or 200-day moving average when you look at the charts.

• • Last week, INVO announced it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.

• • INVO Bioscience, Inc. (INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.

• • INVO’s Management Issued a letter to shareholders recently that spoke to their key developments and future initiatives that have positioned their product INVOcell® within the severely underserved fertility market. PLEASE READ IT HERE.

• • INVO received BUY Ratings from both Roth Capital ($5 PT) & Collier International Securities ( $5.75 PT) in December, 2020.  

• • Recently, INVO filed an 8k highlighting three new partners that they have established to distribute or develop invocell only clinics in Malaysia and North Macedonia.

• • INVO recently announced that it has entered an exclusive distribution agreement with Galaxy Pharma Ltd. to distribute the INVOcell system within Pakistan, the fifth most populous country in the world with approximately 212 million people. Galaxy Pharma is a leader in providing products and services to the country’s current full-service In Vitro Fertilization (IVF) facilities, and has joint ventures operating an additional 21 facilities focused on administering Intrauterine Insemination (IUI) via OBGYN’s.

• Shares of NeuBase Therapeutics (NBSE) closed trading this week at $10.79 up from $9.15/share last week. Last week, NBSE announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc. The technology has demonstrated the ability to resolve disease in genetic models of several human indications. The acquisition was reported to bolster NeuBase’s capabilities and reinforces the Company’s position as a leader in the field of genetic medicine. Read the complete story.

• • The company expects to successfully negotiate a corporate licensing deal of some kind prior to the one-year anniversary of their April, 2020 equity financing as stated in a recent interview.

• • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

• • Recently, NeuBase announced positive in vitro and in vivo preclinical data for its PATrOL™-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBase’s anti-gene approach to comprehensively treat the underlying cause of DM1. Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase stated “Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients. DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1.”

  • Recently, I hosted a FREE Presentation & Q&A Event for our sister organization Tribe Public with the CEO & Founder of NeuBase, Dietrich Stephan, Ph.D., an industry veteran who is considered one of the fathers of the field of precision medicine. The presentation is titled “Accelerating the Genetic Revolution with a New Class of Synthetic Medicines.” You can view the recording at the Tribe Public Channel. 

• We continue to like clean hydrogen solution provider Plug Power (PLUG) closed at $65.77/share up from $63.17 last Friday. It has been a nice ride from the Fall 2020 in the $10.50 range when we identified it. With the significantly bolstered balance sheet, the Biden push for clean energy alternatives and a number of new corporate relationships & initiatives this company continues to impress.  T

• • They recently added $1.8 Billion via another common stock offering at $65/share.

• • Recently, PLUG announced that they are jointly developing hydrogen-powered light commercial vehicles (LCV) with French carmaker Renault.

• • Plug and the SK Group also recently announced that the companies intend to form a strategic partnership to accelerate hydrogen as an alternative energy source in Asian markets. SK Group will make a $1.5 billion (9.9% stake) strategic investment in Plug Power.

• • Recently, PLUG announced that is expanding is relationship with Walmart (WMT).

• • In Q4/2020. PLUG confirmed that they had sold 38M shares priced at $22.25/shares raising a whopping $845.5M which represented about 9.1% of the shares outstanding which brought their capital to the $1.7B range then and now it would seem that they are close to ~3B. 

QUOTE OF WEEK

“In investing, what is comfortable is rarely profitable.” — Robert Arnott

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Investing & Inspiration

“In investing, what is comfortable is rarely profitable.” — Robert Arnott

“Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle

“No Price is too low for a bear or too high for a bull.” — Anonymous

“Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous

“Behind every stock is a company. Find out what it’s doing.” — Peter Lynch

“Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz

“If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart

“It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller

“A bull market is like sex. It feels best just before it ends.” — Barton Biggs

“The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham

“No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea

“The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

“Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham

“Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein

“The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett

“Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch

“Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone

“Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn

“You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 

“We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett

“Never test the depth of the river with both of your feet.” – Warren Buffet

“Know what you own, and know why you own it.” – Peter Lynch

“Liquidity is only there when you don’t need it.” -Old Proverb

“There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray

“If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson

“Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel

“In investing, what is comfortable is rarely profitable.” – Robert Arnott

“Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger

“The entrance strategy is actually more important than the exit strategy.” – Edward Lampert

“The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis

“It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton

“Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier

“Remember that the stock market is a manic depressive.”  – Warren Buffett

“An investment in knowledge pays the best interest.” – Benjamin Franklin

“I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates

“Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman

“The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy

“If all the economists were laid end to end, they’d never reach a conclusion.
-George Bernard Shaw

“The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney

“In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham

“In investing, what is comfortable is rarely profitable.” -Robert Arnott

“The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein

“How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen

“Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky

“Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner

“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru

“I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt

“Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers